■ Glaukos has entered into a licensing agreement with the early-stage life sciences company Intratus. Under terms of the deal, Intratus has granted Glaukos a global exclusive license to research, develop, manufacture, and commercialize Intratus’s patented, noninvasive drug-delivery platform designed for use in the treatment of dry eye disease, glaucoma, and other corneal disorders.

Intratus’s patented cream-based drug formulations are applied to the outer surface of the eyelid for transdermal delivery of pharmaceutically active compounds. Early human studies with this novel delivery system have demonstrated efficacy without the side effects often associated with drugs delivered as topical eye drops, according to a company news release.

“This licensing agreement adds a novel drug-delivery platform using a differentiated, noninvasive transdermal approach to our expanding portfolio of sustained pharmaceutical systems,” said Thomas Burns, Glaukos president and CEO. “Intratus’s proprietary transdermal drug-delivery application is highly complementary to our expanding portfolio of sustained pharmaceutical systems and represents a synergistic fit with our glaucoma and corneal health R&D initiatives.”